Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

Assessing Full Benefit of Rivaroxaban Prophylaxis in High-Risk Ambulatory Patients with Cancer: Thromboembolic Events in the Randomized CASSINI Trial

Introduction In the CASSINI study, rivaroxaban thromboprophylaxis significantly reduced primary venous thromboembolism (VTE) endpoints during the intervention period, but several thromboembolic events designated as secondary efficacy endpoints were not included in the primary analysis. This study wa...

Full description

Bibliographic Details
Main Authors: Alok A. Khorana, Mairéad G. McNamara, Ajay K. Kakkar, Michael B. Streiff, Hanno Riess, Ujjwala Vijapurkar, Simrati Kaul, Peter Wildgoose, Gerald A. Soff
Format: Article
Language:English
Published: Georg Thieme Verlag KG 2020-04-01
Series:TH Open
Subjects:
arterial thrombosis
cancer
thrombolysis/thrombolytic agents
thromboprophylaxis
venous thrombosis
Online Access:http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712143

Internet

http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1712143

Similar Items